ipilimumab,nivolumab
bms
['nsclc', 'lcsm,(-blcsm)', 'sclc', 'lba9026', 'scienceatbms', 'bms']
curious about long-term survival with first-line dual #immunotherapy plus a short course of chemotherapy treatment for patients with metastatic #nsclc? late-breaking 3-year data are coming on june 6 at #asco22; lba9026: #lcsm. 
Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below: